Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies.

The team hunted every human trial that tweaked the brain chemical GABA in people with autism. They screened 1,600-plus papers and kept only 14 that met strict rules: the drug had to hit GABA receptors, and the subjects had to have ASD.

Most studies lasted just weeks and held fewer than the participants. Drugs tested were valproate, acamprosate, and arbaclofen.

No drug showed clear benefit for core autism traits. Side effects were mild and short-term, so safety looked okay, but proof of help was missing.

The authors call the evidence "insufficient." In plain words: we still do not know if these pills work.

Hudson et al. (2012) already warned that only a handful of autism medicines have solid proof. Natascia’s 2016 review zooms in on GABA drugs and reaches the same empty shelf—no new winners.

Weiss et al. (2001) found fewer GABA docking stations in autistic brains. That gap gave the idea for these drugs, yet the clinical trials show fixing the gap is not so simple.

Cicchetti et al. (2014) linked certain GABA gene patterns to autism risk in Argentinean kids. The genes say "target GABA," but the pill data say "target not yet hit." The story is not contradictory; it just shows biology and treatment are two different races.

BCBAs often field parent questions about new pills. This paper gives you a clear, evidence-backed answer: GABA drugs are still experimental. You can reassure families that short-term use seems safe, but you should not delay behavioral treatment while waiting for a GABA magic bullet. Keep teaching skills; let neurology catch up later.